Procena efekata operativnog lečenja benignog uvećanja prostate na simptome donjeg urinarnog trakta i kvalitet života

  • Uros M Babic Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia
  • Ivan Soldatović University of Belgrade, Faculty of Medicine, Institute for Medical Statistics and Informatics; Belgrade, Serbia
  • Ivan Vuković Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia
  • Svetomir Dragićević Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia
  • Dejan Djordjević Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia
  • Miodrag Aćimović Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia
  • Veljko Šantrić Clinical Centre of Serbia, Clinic of Urology, Belgrade, Serbia
  • Zoran Džamić Clinical Centre of Serbia, *Clinic of Urology, Belgrade, Serbia
  • Aleksandar Vuksanović Clinical Centre of Serbia, *Clinic of Urology, Belgrade, Serbia
DOI: https://doi.org/10.2298/VSP170227062B
Ključne reči: prostata, hipertrofija, hirurgija urološka, procedure, preoperativna priprema, postoperativni period, kvalitet života, ankete i upitnici

Sažetak


Apstrakt

 

Uvod/Cilj. Benigno uvećanje prostate ili benigna hiperplazija prostate (BPH) je patološki proces koji vrlo često uzrokuje brojne simptome donjeg urinarnog trakta (Lower Urinary Tract Symptoms – LUTS) i posredno ometa obavljanje dnevnih aktivnosti, umanjuje kvalitet života (Health-Related Quality of Life – HRQoL) muškaraca. Cilj ovog istraživanja bio je procena efekata operativnog lečenja BPH na LUTS i na HRQoL koja je izvršena uz pomoć standardnih kliničkih dijagnostičkih procedura kao i primenom simptom-skora validiranog na srpski jezik. Metode. Sedamdeset četiri bolesnika podvrgnuta su operativnom lečenju zbog BPH. Simptomi mokrenja i inkontinencije mereni su upitnikom Internacionalnog udruženja muške inkontinencije – skraćena forma [International Continence Society Male Short Form (ICS male SF)], a kvalitet života upitnikom SF-36, i to pre i šest meseci nakon operacije. Procena kliničkih efekata operativnog lečenja je utvrđena merenjem toka i jačine mlaza urina tokom uriniranja i količine rezidualnog urina pre i posle operacije. Rezultati. U odnosu na period pre operacije, posle operacije svi bolesnici imali su devetostruko smanjenje učestalosti mokrenja i simptoma inkontinencije. Njihov kvalitet života bio je značajno poboljšan, izrazito u domenu emocionalnog zdravlja. Iako su bili značajno ukupno po­boljšani skorovi mentalne i fizičke komponente kvaliteta života i zdravlja, nivo promene vrednosti skora mokrenja i skora inkontinencije jedino je korelisao sa nivoom promene vrednosti skora mentalnog aspekta kvaliteta života. Za­klju­čak. Posle operacije zbog BPH, bolesnici će vrlo verovatno mokriti uobičajeno, skoro bez nevoljnog mokrenja, imaće značajno bolji kvalitet života, a posebno poboljšanje će biti u domenu emocionalnog zdravlja.

 

Reference

REFERENCES

Irwin DE, Milsom I, Kopp Z, Abrams P, Artibani W, Herschorn S. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: Impact of overactive bladder. Eur Urol (Switzerland) 2009; 56(1): 14–20.

Babic U, Santric-Milicevic M, Terzic Z, Argirovic A, Kojic D, Stjepa-novic M, et al. Impact of Voiding and Incontinence Symptoms on Health-Related Life Quality in Serbian Male Population. Urol J 2015; 12(3): 2196–203.

Abrams P, Manson J, Kirby M. Incidence and epidemiology of storage lower urinary tract symptoms. Eur Urol Rev 2012; 7(1): 50–4.

Coyne KS, Wein AJ, Tubaro A, Sexton CC, Thompson CL, Kopp ZS, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009; 103(Suppl 3): 4–11.

Irwin DE, Mungapen L, Milsom I, Kopp Z, Reeves P, Kelleher C. The economic impact of overactive bladder syndrome in six Western countries. BJU Int 2009; 103(2): 202–9.

Gratzke C, Bachmann A, Descazeaud A, Drake MJ, Madersbacher S, Mamoulakis C, et al. EAU Guidelines on the Assessment of Non-neurogenic Male Lower Urinary Tract Symptoms includ-ing Benign Prostatic Obstruction. Eur Urol 2015;7(6): 1099–109.

Rodrigues Netto N Jr, de Lima ML, de Andrade EF, Apuzzo F, da Silva MB, Davidzon IM, et al. Latin American study on patient acceptance of the International Prostate Symptom Score (IPSS) in the evaluation of symptomatic benign prostatic hyperplasia. Urology 1997; 49(1): 46–9.

Donovan JL, Abrams P, Peters TJ, Kay HE, Reynard J, Chapple C, et al. The ICS-'BPH' Study: The psychometric validity and re-liability of the ICSmale questionnaire. Br J Urol 1996; 77(4): 554–62.

Donovan JL, Peters TJ, Abrams P, Brookes ST, de aa Rosette JJ, Schäfer W. Scoring the short form ICSmaleSF questionnaire. International Continence Society. J Urol 2000; 164(6): 1948–55

Babic U, Santric-Milicevic M, Bjegovic-Mikanovic V, Argirovic A, Stjepanovic M, Lazovic D, et al. Cross-cultural adaptation and validation of the Serbian version of the ICS SF male question-naire. ScientificWorldJournal 2015; 2015: 673196.

Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30(6): 473–83.

Ware JE. Measuring patients' views: The optimum outcome measure. BMJ 1993; 306(6890): 1429–30.

Cronbach LJ. Coefficient alpha and the internal structure of tests. Psychometrika 1951; 16(3): 297–334.

Speakman M, Kirby R, Doyle S, Ioannou C. Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): Focus on the UK. BJU Int 2015; 115(4): 508–19.

Emberton M, Fitzpatrick JM, Garcia-Losa M, Qizilbash N, Djavan B. Progression of benign prostatic hyperplasia: Systematic re-view of the placebo arms of clinical trials. BJU Int 2008; 102(8): 981–6.

Verhamme KM, Dieleman JP, van Wijk MA, Bosch JL, Stricker BH, Sturkenboom MC. Low incidence of acute urinary retention in the general male population: the triumph project. Eur Urol 2005; 47(4): 494–8.

Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gomez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: A guide to the risk factors and options for medical management. Int J Clin Pract 2008; 62(7): 1076–86.

Crawford ED, Wilson SS, McConnell JD, Slawin KM, Lieber MC, Smith JA, et al. Baseline factors as predictors of clinical pro-gression of benign prostatic hyperplasia in men treated with placebo. J Urol 2006; 175(4): 1422–6; discussion 1426-7.

Kolman C, Girman CJ, Jacobsen SJ, Lieber MM. Distribution of post-void residual urine volume in randomly selected men. J Urol 1999; 161(1): 122–7.

Mochtar CA, Kiemeney LA, van Riemsdijk MM, Laguna MP, De-bruyne FM, de la Rosette JJ. Post-void residual urine volume is not a good predictor of the need for invasive therapy among patients with benign prostatic hyperplasia. J Urol 2006; 175(1): 213–6.

Varkarakis I, Kyriakakis Z, Delis A, Protogerou V, Deliveliotis C. Long-term results of open transvesical prostatectomy from a contemporary series of patients. Urology 2004; 64(2): 306–10.

Hakenberg OW, Pinnock CB, Marshall VR. Preoperative urody-namic and symptom evaluation of patients undergoing transu-rethral prostatectomy: Analysis of variables relevant for out-come. BJU Int 2003; 91(4): 375–9.

Lee SW, Choi JB, Lee KS, Kim TH, Son H, Jung TY, et al. Tran-surethral procedures for lower urinary tract symptoms result-ing from benign prostatic enlargement: a quality and meta-analysis. Int Neurourol J 2013; 17(2): 59–66.

Bruskewitz R. Management of symptomatic BPH in the US: Who is treated and how? Eur Urol 1999; 36(Suppl 3): 7–13.

Ahlstrand C, Carlsson P, Jonsson B. An estimate of the life-time cost of surgical treatment of patients with benign prostatic hyperplasia in Sweden. Scand J Urol Nephrol 1996; 30(1): 37–43.

Lukacs B. Management of symptomatic BPH in France: Who is treated and how? Eur Urol 1999; 36(Suppl 3): 14–20.

Serretta V, Morgia G, Fondacaro L, Curto G, Lo Bianco A, Pirritano D, et al. Open prostatectomy for benign prostatic enlargement in southern Europe in the late 1990s: A contemporary series of 1800 interventions. Urology 2002; 60(4): 623–7.

Mozes B, Cohen YC, Olmer L, Shabtai E. Factors affecting change in quality of life after prostatectomy for benign prostatic hypertrophy: The impact of surgical techniques. J Urol 1996; 155(1): 191–6.

Ahyai SA, Lehrich K, Kuntz RM. Holmium laser enucleation versus transurethral resection of the prostate: 3-year follow-up results of a randomized clinical trial. Eur Urol 2007; 52(5): 1456–63.

Kallenberg F, Hossack TA, Woo HH. Long-term followup after electrocautery transurethral resection of the prostate for be-nign prostatic hyperplasia. Adv Urol 2011; 2011: 359478.

Hunter DJ, McKee M, Black NA, Sanderson CF. Health status and quality of life of British men with lower urinary tract symptoms: Rresults from the SF-36. Urology 1995; 45(6): 962–71.

Engstrom G, Henningsohn L, Walker-Engstrom ML, Leppert J. Impact on quality of life of different lower urinary tract symp-toms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol 2006; 40(6): 485–94.

Welch G, Weinger K, Barry MJ. Quality-of-life impact of lower urinary tract symptom severity: Results from the Health Pro-fessionals Follow-up Study. Urology 2002; 59(2): 245–50.

Quek KF. Factors affecting health-related quality of life among patients with lower urinary tract symptoms. Int J Urol 2005; 12(12): 1032–6.

Haltbakk J, Hanestad BR, Hunskaar S. How important are mens lower urinary tract symptoms (LUTS) and their impact on the quality of life (QOL). Qual Life Res 2005; 14(7): 1733–41.

Objavljeno
2021/01/26
Broj časopisa
Vol. 76 Br. 1 (2019): Vol. 76 Br. 1 (2019): Vojnosanit Pregl 2019; January Vol. 76 (No. 1)
Rubrika
Originalni članak